

THALLIUM IMAGING TEST ANALYSIS
(FOR THALLIUM CORE LAB USE)

Clinic No.			-				
ID No.			-				
Form Type	X	A					

PART I: IDENTIFICATION

1. Patient's NAME CODE: -----
2. Date of study: ----- fm8gday

Month	Day	Year
-------	-----	------
3. Identify this test: ----- clthtyp2

(1)	(2)	(3)
ETT	Persantine	Adenosine
4. Time of test: thaltyp2

Pre-discharge or within 5 days after hospital discharge -----	(1)
Six-week follow-up (42 to 70 days) -----	(2)
Follow-up Thallium (71 to 182 days) -----	(3)
Other -----	(4)
5. If test was completely uninterpretable, check here and skip to Item 24 ----- uninterp (1)
6. Data received: (Check as appropriate.)

A. Field Flood -----	flood	(1)
B. Bar Phantom -----	phantom	(1)
C. Injection site counts -----	inisite	(1)
D. LAO EX -----	laoex	(1)
E. LLAT EX -----	llatex	(1)
F. ANT EX -----	antex	(1)
G. Breast marker LAO EX -----	bmlaoex	(1)
H. Breast marker LLAT EX -----	bmllatex	(1)
I. Breast marker ANT EX -----	bmantex	(1)
J. LAO D (2-2.5 hr) -----	laod	(1)
K. LLAT D -----	llatd	(1)
L. ANT D -----	antd	(1)
M. Breast marker LAO D -----	bmlaod	(1)
N. Breast marker LLAT D -----	bmllatd	(1)
O. Breast marker ANT D -----	bmantd	(1)
P. LAO R (24 hours) -----	laor	(1)
Q. LLAT R -----	llatr	(1)
R. ANT R -----	antr	(1)
S. Breast marker LAO R -----	bmlaor	(1)
T. Breast marker LLAT R -----	bmllatr	(1)
U. Breast marker ANT R -----	bmantr	(1)

ID No.			-				
--------	--	--	---	--	--	--	--

7. Number of views:

		<u>Yes</u>	<u>No</u>
A. Complete EX	----- complex	(1)	(2)
B. Complete D	----- compd	(1)	(2)
C. Complete R (24 hours)	----- compr	(1)	(2)
D. Breast markers	----- markers	(1)	(2)

PART II: QUALITY CONTROL

8. Study type:

	<u>Fully</u> <u>Satisfactory</u>	<u>Satisfactory</u> <u>for Visual</u> <u>Analysis Only</u>	<u>Unsatis-</u> <u>factory</u>	<u>Not</u> <u>Done</u>
A. Immediately post-exercise	----- postexer (1)	(2)	(3)	(4)
B. Delayed	----- delayed (1)	(2)	(3)	(4)
C. Rest (24 hours)	----- rest (1)	(2)	(3)	(4)

9. Overall quality of study:

Excellent	-----	(1)
Good	-----	(2)
Average	-----	(3)
Poor	-----	(4)

10. Were there any technical problems? ----- tptprob Yes No
 (1) (2)
 ↓

A. Extravascular injection?	----- evini	(1)	(2)
B. Inadequate counts?	----- inadct	(1)	(2)
C. Inadequate resolution?	----- inaores	(1)	(2)
D. Nonuniformity?	----- nonuni	(1)	(2)
E. Patient motion?	----- motion	(1)	(2)
F. Patient position inconsistent or incorrect?	----- position	(1)	(2)
G. Breast attenuation?	----- breast	(1)	(2)
H. Non-planar imaging?, e.g. SPECT	----- nonplan	(1)	(2)
I. Other	----- othtech	(1)	(2)
Specify _____			

ID No.									
Form Type	X	A							

PART III: VISUAL ANALYSIS

These data should only be interpreted from the exercise and 2 to 2 1/2 hour delayed imaging scans, not from the 24-hour rest study.

dilheart

11. Enlarged, dilated heart? ----- (1) (2)
 Yes No

12. Visual segment analysis:

	<u>Fixed</u>	<u>Partial Redistri- bution</u>	<u>Complete Redistri- bution</u>	<u>Normal</u>	<u>Reverse Redistri- bution</u>	<u>Un inter- pretable</u>
A. LAO:						laous
1) Upper septum	(1)	(2)	(3)	(4)	(5)	(6) laols
2) Lower septum	(1)	(2)	(3)	(4)	(5)	(6) laoapx
3) Apex	(1)	(2)	(3)	(4)	(5)	(6) laoil
4) Inferolateral	(1)	(2)	(3)	(4)	(5)	(6) laopl
5) Posterolateral	(1)	(2)	(3)	(4)	(5)	(6)
B. LLAT:						llatab
1) Anterobasal	(1)	(2)	(3)	(4)	(5)	(6) llatant
2) Anterior	(1)	(2)	(3)	(4)	(5)	(6) llatapx
3) Apex	(1)	(2)	(3)	(4)	(5)	(6) llatinf
4) Inferior	(1)	(2)	(3)	(4)	(5)	(6) llatpb
5) Posterobasal	(1)	(2)	(3)	(4)	(5)	(6)
C. ANT:						antis
1) Inferoseptal	(1)	(2)	(3)	(4)	(5)	(6) antas
2) Apical septum	(1)	(2)	(3)	(4)	(5)	(6) antapx
3) Apex	(1)	(2)	(3)	(4)	(5)	(6) antal
4) Anterolateral	(1)	(2)	(3)	(4)	(5)	(6) antab
5) Anterobasal	(1)	(2)	(3)	(4)	(5)	(6)

ID No.			-					
Form Type	X	A						

13. Abnormal lung uptake? ----- **ablung** ----- (1) (2)
 Yes No
 ↓

A. Abnormality: abamt Mild to Moderate (1) Severe (2)
--

14. Transient LV dilatation? ----- **dilate** ----- (1) (2)
 Yes No

15. Regions with reversible hypoperfusion (Visual): (*Answer each item.*)

		<u>Yes</u>	<u>No</u>
A. Anterior (B ₁ , B ₂ , C ₄ , or C ₅)	----- antisc -----	(1)	(2)
B. Septum (A ₁ or A ₂)	----- sepisc -----	(1)	(2)
C. Lateral (A ₄ or A ₅)	----- latisc -----	(1)	(2)
D. Inferoapical (A ₃ contiguous with A ₂)	----- iaisc -----	(1)	(2)
E. Inferior (B ₄ , B ₅ , C ₁ , or C ₂)	----- infisc -----	(1)	(2)
F. Non-contiguous apical (A ₃ , B ₃ , or C ₃)	----- apcisc -----	(1)	(2)

(Counted as separate region only if non-contiguous with other region(s) with reversible hypoperfusion)

ID No.			-					
Form Type	X	A						

PART IV: QUANTITATIVE ANALYSIS

These data should only be interpreted from the exercise and 2 to 2 1/2 hour delayed imaging scans, not from the 24-hour rest study.

16. Quantitative regional thallium uptake:

	1) <u>Exercise</u> <u>Defect Score</u>	2) <u>Maximal Change</u> <u>on Delayed</u> <u>(+/-)*</u>
A. LAO:		
1) Upper septum -----	<u>laousrua</u>	<u>laousrub</u>
2) Lower septum -----	<u>laolsrua</u>	<u>laolsrub</u>
3) Apex -----	<u>laoaprua</u>	<u>laoaprub</u>
4) Inferolateral -----	<u>laoilrua</u>	<u>laoilrub</u>
5) Posterolateral -----	<u>laoplrua</u>	<u>laoplrub</u>
B. LLAT:		
1) Anterobasal -----	<u>latabrua</u>	<u>latabrub</u>
2) Anterior -----	<u>latanrua</u>	<u>latanrub</u>
3) Apex -----	<u>lataprua</u>	<u>lataprub</u>
4) Inferior -----	<u>latinrua</u>	<u>latinrub</u>
5) Posterobasal -----	<u>latpbrua</u>	<u>latpbrub</u>
C. ANT:		
1) Inferoseptal -----	<u>antisrua</u>	<u>antisrub</u>
2) Apical septum -----	<u>antasrua</u>	<u>antasrub</u>
3) Apex -----	<u>antaprua</u>	<u>antaprub</u>
4) Anterolateral -----	<u>antalrua</u>	<u>antalrub</u>
5) Anterobasal -----	<u>antabrua</u>	<u>antabrub</u>

17. Total defect integral:

A. Exercise defect integral -----	exdefint
B. Change at delayed imaging -----	chdelim
C. Relative change on delayed imaging -----	(+/)* relchang
	(+/)*

18. Lung washout: ----- washout %

19. Lung/heart ratio: ----- lhratio

* + = reverse redistribution
 - = redistribution

ID No.									
Form Type	X	A							

20. Total defect integral:

- None (0-2) ----- integral ----- (1)
 Small (3-5) ----- (2)
 Moderate (6-12) ----- (3)
 Large (\geq 13) ----- (4)

21. Total percent reversibility:

- Insignificant (\leq 25%) ----- reversal ----- (1)
 Mild to moderate (26-49%) ----- (2)
 Large (\geq 50%) ----- (3)

22. Conclusion combining visual and quantitative analysis: (Answer each item.)

- | | | <u>Yes</u> | <u>No</u> |
|--|-----------------|------------|-----------|
| A. No perfusion abnormality (normal) ----- | <u>noabnorm</u> | (1) | (2) |
| B. Scar ----- | <u>scar</u> | (1) | (2) |
| C. Reversible hypoperfusion ----- | <u>clischem</u> | (1) | (2) |
| D. Lung uptake with reversible hypoperfusion ----- | <u>luischem</u> | (1) | (2) |
| E. Transient LV dilatation ----- | <u>cldilate</u> | (1) | (2) |
| F. Reverse redistribution ----- | <u>revdis</u> | (1) | (2) |
| G. Regions with reversible hypoperfusion (Visual & Quantitative):
(Answer each item.) | | | |
| 1) Anterior (B_1 , B_2 , C_4 , or C_5) ----- | <u>antterr</u> | (1) | (2) |
| 2) Septum (A_1 or A_2) ----- | <u>septerr</u> | (1) | (2) |
| 3) Lateral (A_4 or A_5) ----- | <u>latterr</u> | (1) | (2) |
| 4) Inferoapical (A_3 contiguous with A_2) ----- | <u>iapterr</u> | (1) | (2) |
| 5) Inferior (B_4 , B_5 , C_1 , or C_2) ----- | <u>infterr</u> | (1) | (2) |
| 6) Non-contiguous apical (A_3 , B_3 , or C_3) ----- | <u>ncapterr</u> | (1) | (2) |
| (Counted as separate zone only if non-contiguous with other region(s) of reversible hypoperfusion) | | | |

ID No.			-					
Form Type	X	A						

23. High risk patient? ----- highrisk (1) (2)
 Yes No
 ↓

A. Answer each item:		Yes	No
<u>Visual</u>	1) ≥ 2 regions with ----- reversible hypoperfusion	<u>twoterr</u> (1)	(2)
	2) Lung uptake <u>and</u> ≥ 1 region --- with reversible hypoperfusion	<u>luandis</u> (1)	(2)
<u>Quantitative</u>	3) Lung washout $> 42\%$ -----	<u>highwash</u> (1)	(2)
	4) Lung/heart ratio > 0.5 -----	<u>hiratio</u> (1)	(2)
	5) Defect integral ≥ 13 <u>and</u> ----- reversibility $\geq 50\%$	<u>double</u> (1)	(2)

PART V: ADMINISTRATIVE MATTERS

24. Thallium Core Lab Investigator:

Signature: _____ T3 Staff No.: _____ - _____

25. Date form completed: -----
 _____ - _____ - _____
 Month Day Year

ID No.			-						
Form Type	X	A							

T3 Form 8G: Variables from earlier revisions

CLTHTYPE Revision 1 Item 3
Identify this test
1=ETT 2=Persantine

THALTYPE Revision 1 Item 4
Time of test
1=Pre-discharge or within 5 days after hospital discharge
2=Six-week follow-up (42 to 70 days)
3=Follow-up Thallium (71 to 182 days)
4=Other

DILINDEX Revision 1 Item 19
Dilatation index

CLLVDIL Revision 1 Item 23A3
High risk patient? answered Yes
Visual: Transient LV dilatation
1=Yes 2=No

HIDILATE Revision 1 Item 23A6
High risk patient? Answered Yes
Quantitative: Dilatation index > 1.1
1=Yes 2=No

T3 Form 8G: Data Set Revisions

The following item was recoded:

Item 19: Lung/heart ratio

4 records changed from 9.98 to missing

T3B form8g

The CONTENTS Procedure

Data Set Name:	WORK.FORM8G	Observations:	1608
Member Type:	DATA	Variables:	128
Engine:	V8	Indexes:	0
Created:	14:52 Wednesday, February 11, 2004	Observation Length:	544
Last Modified:	14:52 Wednesday, February 11, 2004	Deleted Observations:	0
Protection:		Compressed:	NO
Data Set Type:		Sorted:	NO
Label:			

----Alphabetic List of Variables and Attributes----					
#	Variable	Type	Len	Pos	Label
61	ABAMT	Num	4	256	f8Gq13A: Lung uptake abnormality
60	ABLUNG	Num	4	252	f8Gq13: Abnormal lung uptake
50	ANTAB	Num	4	212	f8Gq12C5: ANT analysis anterobasal
79	ANTABRUA	Num	4	308	f8Gq16C5A: ANT quant anterobasal score
80	ANTABRUB	Num	5	469	f8Gq16C5B: ANT quant anterobasal change
51	ANTAL	Num	4	216	f8Gq12C4: ANT analysis anterolateral
81	ANTALRUA	Num	4	312	f8Gq16C4A: ANT quant anterolateral score
82	ANTALRUB	Num	5	474	f8Gq16C4B: ANT quant anterolateral chang
83	ANTAPRUA	Num	4	316	f8Gq16C3A: ANT quant apex score
84	ANTAPRUB	Num	5	479	f8Gq16C3B: ANT quant apex change
52	ANTAPX	Num	4	220	f8Gq12C3: ANT analysis apex
53	ANTAS	Num	4	224	f8Gq12C2: ANT analysis apical septum
85	ANTASRUA	Num	4	320	f8Gq16C2A: ANT quant apical septum score
86	ANTASRUB	Num	5	484	f8Gq16C2B: ANT quant apical septum chang
18	ANTD	Num	4	84	f8Gq6L: ANT D
12	ANTEX	Num	4	60	f8Gq6F: ANT EX
54	ANTIS	Num	4	228	f8Gq12C1: ANT analysis inferoseptal
63	ANTISC	Num	4	264	f8Gq15A: Reversible hypoperfusion visual
87	ANTISRUA	Num	4	324	f8Gq16C1A: ANT quant inferoseptal score
88	ANTISRUB	Num	5	489	f8Gq16C1B: ANT quant inferoseptal change
24	ANTR	Num	4	108	f8Gq6R: ANT R
113	ANTTERR	Num	4	384	f8Gq22G1: Reversible hypoperfusion concl

(11FEB04--14:52)

T3B form8g**The CONTENTS Procedure**

-----Alphabetic List of Variables and Attributes-----					
#	Variable	Type	Len	Pos	Label
68	APCISC	Num	4	284	f8Gq15F: Reversible hypoperfusion visual
21	BMANTD	Num	4	96	f8Gq6O: Breast marker ANT D
15	BMANTEX	Num	4	72	f8Gq6I: Breast marker ANT EX
27	BMANTR	Num	4	120	f8Gq6U: Breast marker ANT R
19	BMLAOD	Num	4	88	f8Gq6M: Breast marker LAO D
13	BMLAOEX	Num	4	64	f8Gq6G: Breast marker LAO EX
25	BMLAOR	Num	4	112	f8Gq6S: Breast marker LAO R
20	BMLLATD	Num	4	92	f8Gq6N: Breast marker LLAT D
14	BMLLATEX	Num	4	68	f8Gq6H: Breast marker LLAT EX
26	BMLLATR	Num	4	116	f8Gq6T: Breast marker LLAT R
43	BREAST	Num	4	184	f8Gq10G: Breast attenuation
100	CHDELIM	Num	5	524	f8Gq17B: Change at delayed imaging
111	CLDILATE	Num	4	376	f8Gq22E: Transient LV dilatation
109	CLISCHEM	Num	4	368	f8Gq22C: Reversible hypoperfusion
122	CLLV DIL	Num	4	420	f8Gq23A3: Visual transient LV dilatation
4	CLTH TYP2	Num	4	28	f8Gq3: Identify test
3	CLTH TYPE	Num	4	24	f8Gq3: Identify test
29	COMPD	Num	4	128	f8Gq7B: Complex D
28	COMPEX	Num	4	124	f8Gq7A: Complex EX
30	COMPR	Num	4	132	f8Gq7C: Complex R
33	DELAYED	Num	4	144	f8Gq8B: Delayed study quality
62	DILATE	Num	4	260	f8Gq14: Transient LV dilatation
44	DILHEART	Num	4	188	f8Gq11: Enlarged heart
104	DILINDEX	Num	5	539	f8Gq19: Dilatation index
126	DOUBLE	Num	4	436	f8Gq23A5: Quant defect integral >=13 and
37	EVINJ	Num	4	160	f8Gq10A: Extravascular injection
99	EXDEFINT	Num	5	519	f8Gq17A: Exercise defect integral
7	FLOOD	Num	4	40	f8Gq6A: Field flood
128	FM8GDAY	Num	8	16	f8Gq2: Days to form
2	FMTYP	Char	4	440	Form Type
125	HIDILATE	Num	4	432	f8Gq23A6: Dilatation index > 1.1

(11FEB04--14:52)

T3B form8g**The CONTENTS Procedure**

-----Alphabetic List of Variables and Attributes-----					
#	Variable	Type	Len	Pos	Label
119	HIGHRISK	Num	4	408	f8Gq23: High risk patient
123	HIGHWASH	Num	4	424	f8Gq23A3: Quant lung washout > 42%
124	HIRATIO	Num	4	428	f8Gq23A4: Quant lung//heart ratio > 0.5
66	IAISC	Num	4	276	f8Gq15D: Reversible hypoperfusion visual
116	IAPTERR	Num	4	396	f8Gq22G4: Reversible hypoperfusion concl
38	INADCT	Num	4	164	f8Gq10B: Inadequate counts
39	INAORES	Num	4	168	f8Gq10C: Inadequate resolution
67	INFISC	Num	4	280	f8Gq15E: Reversible hypoperfusion visual
117	INFTEERR	Num	4	400	f8Gq22G5: Reversible hypoperfusion concl
9	INJSITE	Num	4	48	f8Gq6C: Injection site counts
105	INTEGRAL	Num	4	352	f8Gq20: Total defect integral
73	LAOAPRUA	Num	4	296	f8Gq16A3A: LAO quant apex score
74	LAOAPRUB	Num	5	454	f8Gq16A3B: LAO quant apex change
47	LAOAPX	Num	4	200	f8Gq12A3: LAO analysis apex
16	LAOD	Num	4	76	f8Gq6J: LAO D
10	LAOEX	Num	4	52	f8Gq6D: LAO EX
48	LAOIL	Num	4	204	f8Gq12A4: LAO analysis inferolateral
75	LAOILRUA	Num	4	300	f8Gq16A4A: LAO quant inferolateral score
76	LAOILRUB	Num	5	459	f8Gq16A4B: LAO quant inferolateral chang
46	LAOLS	Num	4	196	f8Gq12A2: LAO analysis lower septum
71	LAOLSRUA	Num	4	292	f8Gq16A2A: LAO quant lower septum score
72	LAOLSRUB	Num	5	449	f8Gq16A2B: LAO quant lower septum change
49	LAOPL	Num	4	208	f8Gq12A5: LAO analysis posterolateral
77	LAOPLRUA	Num	4	304	f8Gq16A5A: LAO quant posterolateral scor
78	LAOPLRUB	Num	5	464	f8Gq16A5B: LAO quant posterolateral chan
22	LAOR	Num	4	100	f8Gq6P: LAO R
45	LAOUS	Num	4	192	f8Gq12A1: LAO analysis upper septum
69	LAOUSRUA	Num	4	288	f8Gq16A1A: LAO quant upper septum score
70	LAOUSRUB	Num	5	444	f8Gq16A1B: LAO quant upper septum change
89	LATABRUA	Num	4	328	f8Gq16B1A: LLAT quant anterobasal score
90	LATABRUB	Num	5	494	f8Gq16B1B: LLAT quant anterobasal change

(11FEB04--14:52)

T3B form8g**The CONTENTS Procedure**

-----Alphabetic List of Variables and Attributes-----					
#	Variable	Type	Len	Pos	Label
91	LATANRUA	Num	4	332	f8Gq16B2A: LLAT quant anterior score
92	LATANRUB	Num	5	499	f8Gq16B2B: LLAT quant anterior change
93	LATAPRUA	Num	4	336	f8Gq16B3A: LLAT quant apex score
94	LATAPRUB	Num	5	504	f8Gq16B3B: LLAT quant apex change
95	LATINRUA	Num	4	340	f8Gq16B4A: LLAT quant inferior score
96	LATINRUB	Num	5	509	f8Gq16B4B: LLAT quant inferior change
65	LATISC	Num	4	272	f8Gq15C: Reversible hypoperfusion visual
97	LATPBRUA	Num	4	344	f8Gq16B5A: LLAT quant posterobasal score
98	LATPBRUB	Num	5	514	f8Gq16B5B: LLAT quant posterobasal chang
115	LATTERR	Num	4	392	f8Gq22G3: Reversible hypoperfusion concl
103	LHRATIO	Num	5	534	f8Gq19: Lung/heart ratio
55	LLATAB	Num	4	232	f8Gq12B1: LLAT analysis anterobasal
56	LLATANT	Num	4	236	f8Gq12B2: LLAT analysis anterior
57	LLATAPX	Num	4	240	f8Gq12B3: LLAT analysis apex
17	LLATD	Num	4	80	f8Gq6K: LLAT D
11	LLATEX	Num	4	56	f8Gq6E: LLAT EX
58	LLATINF	Num	4	244	f8Gq12B4: LLAT analysis inferior
59	LLATPB	Num	4	248	f8Gq12B5: LLAT analysis posterobasal
23	LLATR	Num	4	104	f8Gq6Q: LLAT R
121	LUANDIS	Num	4	416	f8Gq23A2: Visual lung uptake & reversibl
110	LUISCHEM	Num	4	372	f8Gq22D: Lung uptake with reversible hyp
31	MARKERS	Num	4	136	f8Gq7D: Breast markers
41	MOTION	Num	4	176	f8Gq10E: Patient motion
118	NCAPTERR	Num	4	404	f8Gq22G6: Reversible hypoperfusion concl
127	NEWID	Num	8	8	Patient Identification
107	NOABNORM	Num	4	360	f8Gq22A: No perfusion abnormality
40	NONUNI	Num	4	172	f8Gq10D: Nonuniformity
8	PHANTOM	Num	4	44	f8Gq6B: Bar phantom
42	POSITION	Num	4	180	f8Gq10F: Patient position
32	POSTEXER	Num	4	140	f8Gq8A: Post exercise study quality
101	RELCHANG	Num	5	529	f8Gq17C: Relative change on delayed imag

(11FEB04--14:52)

T3B form8g**The CONTENTS Procedure**

-----Alphabetic List of Variables and Attributes-----					
#	Variable	Type	Len	Pos	Label
34	REST	Num	4	148	f8Gq8C: Rest study quality
1	REV	Num	8	0	Revision
112	REVDIS	Num	4	380	f8Gq22F: Reversible redistribution
106	REVERSAL	Num	4	356	f8Gq21: Total percent reversibility
108	SCAR	Num	4	364	f8Gq22B: Scar
64	SEPISC	Num	4	268	f8Gq15B: Reversible hypoperfusion visual
114	SEPTERR	Num	4	388	f8Gq22G2: Reversible hypoperfusion concl
6	THALTYP2	Num	4	36	f8Gq4: Time of test
5	THALTYPE	Num	4	32	f8Gq4: Time of test
36	TPTPROB	Num	4	156	f8Gq10: Technical problems
35	TPTQUAL	Num	4	152	f8Gq9: Overall study quality
120	TWOTERR	Num	4	412	f8Gq23A1: Visual 2 or more reversible hy
102	WASHOUT	Num	4	348	f8Gq18: Lung washout

T3B form8g

Variable	Label	Value	N	%	<= 20
REV	Revision	0	45	2.8	
		1	398	24.8	
		2	861	53.5	
		3	304	18.9	
FMTYP	Form Type	XA01	1331	82.8	
		XA02	273	17.0	
		XA03	4	0.2	*
CLHTYP2	f8Gq3: Identify test	.	1306	81.2	
		1	269	16.7	
		2	30	1.9	
		3	3	0.2	*
CLHTYPE	f8Gq3: Identify test	.	349	21.7	
		1	1139	70.8	
		2	120	7.5	
THALTYP2	f8Gq4: Time of test	.	444	27.6	
		1	973	60.5	
		2	172	10.7	
		3	9	0.6	*
		4	10	0.6	*
THALTYPE	f8Gq4: Time of test	.	1165	72.5	
		1	345	21.5	
		2	96	6.0	
		3	2	0.1	*
FLOOD	f8Gq6A: Field flood	.	1270	79.0	
		1	338	21.0	

(11FEB04--14:52)

T3B form8g

Variable	Label	Value	N	%	<= 20
PHANTOM	f8Gq6B: Bar phantom	.	1396	86.8	
		1	212	13.2	
INJSITE	f8Gq6C: Injection site counts	.	1454	90.4	
		1	154	9.6	
LAOEX	f8Gq6D: LAO EX	.	50	3.1	
		1	1558	96.9	
LLATEX	f8Gq6E: LLAT EX	.	44	2.7	
		1	1564	97.3	
ANTEX	f8Gq6F: ANT EX	.	47	2.9	
		1	1561	97.1	
BMLAOEX	f8Gq6G: Breast marker LAO EX	.	1138	70.8	
		1	470	29.2	
BMLLATEX	f8Gq6H: Breast marker LLAT EX	.	1153	71.7	
		1	455	28.3	
BMANTEX	f8Gq6I: Breast marker ANT EX	.	1138	70.8	
		1	470	29.2	
LAOD	f8Gq6J: LAO D	.	63	3.9	
		1	1545	96.1	
LLATD	f8Gq6K: LLAT D	.	53	3.3	
		1	1555	96.7	
ANTD	f8Gq6L: ANT D	.	65	4.0	
		1	1543	96.0	

(11FEB04--14:52)

T3B form8g

Variable	Label	Value	N	%	<= 20
BMLAOD	f8Gq6M: Breast marker LAO D	.	1196	74.4	
		1	412	25.6	
BMLLATD	f8Gq6N: Breast marker LLAT D	.	1217	75.7	
		1	391	24.3	
BMANTD	f8Gq6O: Breast marker ANT D	.	1216	75.6	
		1	392	24.4	
LAOR	f8Gq6P: LAO R	.	1346	83.7	
		1	262	16.3	
LLATR	f8Gq6Q: LLAT R	.	1356	84.3	
		1	252	15.7	
ANTR	f8Gq6R: ANT R	.	1358	84.5	
		1	250	15.5	
BMLAOR	f8Gq6S: Breast marker LAO R	.	1567	97.5	
		1	41	2.5	
BMLLATR	f8Gq6T: Breast marker LLAT R	.	1569	97.6	
		1	39	2.4	
BMANTR	f8Gq6U: Breast marker ANT R	.	1569	97.6	
		1	39	2.4	
COMPEX	f8Gq7A: Complex EX	.	31	1.9	
		1	1575	97.9	
		2	2	0.1	*

T3B form8g

Variable	Label	Value	N	%	<= 20
COMPD	f8Gq7B: Complex D	.	31	1.9	
		1	1566	97.4	
		2	11	0.7	*
COMPR	f8Gq7C: Complex R	.	33	2.1	
		1	252	15.7	
		2	1323	82.3	
MARKERS	f8Gq7D: Breast markers	.	32	2.0	
		1	461	28.7	
		2	1115	69.3	
POSTEXER	f8Gq8A: Post exercise study quality	.	30	1.9	
		1	1551	96.5	
		2	20	1.2	*
		3	7	0.4	*
DELAYED	f8Gq8B: Delayed study quality	.	30	1.9	
		1	1545	96.1	
		2	19	1.2	*
		3	6	0.4	*
		4	8	0.5	*
REST	f8Gq8C: Rest study quality	.	31	1.9	
		1	244	15.2	
		2	3	0.2	*
		3	5	0.3	*
		4	1325	82.4	

(11FEB04--14:52)

T3B form8g

Variable	Label	Value	N	%	<= 20
TPTQUAL	f8Gq9: Overall study quality	.	31	1.9	
		1	323	20.1	
		2	659	41.0	
		3	541	33.6	
		4	54	3.4	
TPTPROB	f8Gq10: Technical problems	.	30	1.9	
		1	304	18.9	
		2	1274	79.2	
EVINJ	f8Gq10A: Extravascular injection	.	1310	81.5	
		1	2	0.1	*
		2	296	18.4	
INADCT	f8Gq10B: Inadequate counts	.	1310	81.5	
		1	71	4.4	
		2	227	14.1	
INAORES	f8Gq10C: Inadequate resolution	.	1310	81.5	
		1	73	4.5	
		2	225	14.0	
NONUNI	f8Gq10D: Nonuniformity	.	1310	81.5	
		1	5	0.3	*
		2	293	18.2	
MOTION	f8Gq10E: Patient motion	.	1310	81.5	
		1	9	0.6	*
		2	289	18.0	

T3B form8g

Variable	Label	Value	N	%	<= 20
POSITION	f8Gq10F: Patient position	.	1310	81.5	
		1	64	4.0	
		2	234	14.6	
BREAST	f8Gq10G: Breast attenuation	.	1310	81.5	
		1	134	8.3	
		2	164	10.2	
DILHEART	f8Gq11: Enlarged heart	.	82	5.1	
		1	242	15.0	
		2	1284	79.9	
LAOUS	f8Gq12A1: LAO analysis upper septum	.	37	2.3	
		1	59	3.7	
		2	41	2.5	
		3	59	3.7	
		4	1373	85.4	
		5	19	1.2	*
		6	20	1.2	*
LAOLS	f8Gq12A2: LAO analysis lower septum	.	37	2.3	
		1	53	3.3	
		2	49	3.0	
		3	95	5.9	
		4	1339	83.3	
		5	24	1.5	
		6	11	0.7	*

(11FEB04--14:52)

T3B form8g

Variable	Label	Value	N	%	<= 20
LAOAPX	f8Gq12A3: LAO analysis apex	.	36	2.2	
		1	167	10.4	
		2	93	5.8	
		3	123	7.6	
		4	1141	71.0	
		5	40	2.5	
		6	8	0.5	*
LAOIL	f8Gq12A4: LAO analysis inferolateral	.	36	2.2	
		1	132	8.2	
		2	71	4.4	
		3	86	5.3	
		4	1184	73.6	
		5	82	5.1	
		6	17	1.1	*
LAOPL	f8Gq12A5: LAO analysis posterolateral	.	36	2.2	
		1	75	4.7	
		2	27	1.7	
		3	33	2.1	
		4	1377	85.6	
		5	40	2.5	
		6	20	1.2	*
LLATAB	f8Gq12B1: LLAT analysis anterobasal	.	39	2.4	
		1	62	3.9	
		2	33	2.1	
		3	47	2.9	
		4	1368	85.1	
		5	20	1.2	*
		6	39	2.4	

(11FEB04--14:52)

T3B form8g

Variable	Label	Value	N	%	<= 20
LLATANT	f8Gq12B2: LLAT analysis anterior	.	39	2.4	
		1	137	8.5	
		2	72	4.5	
		3	98	6.1	
		4	1187	73.8	
		5	34	2.1	
		6	41	2.5	
LLATAPX	f8Gq12B3: LLAT analysis apex	.	39	2.4	
		1	243	15.1	
		2	91	5.7	
		3	95	5.9	
		4	1065	66.2	
		5	42	2.6	
		6	33	2.1	
LLATINF	f8Gq12B4: LLAT analysis inferior	.	39	2.4	
		1	88	5.5	
		2	55	3.4	
		3	61	3.8	
		4	1309	81.4	
		5	27	1.7	
		6	29	1.8	
LLATPB	f8Gq12B5: LLAT analysis posterobasal	.	39	2.4	
		1	103	6.4	
		2	45	2.8	
		3	53	3.3	
		4	1313	81.7	
		5	24	1.5	
		6	31	1.9	

(11FEB04--14:52)

T3B form8g

Variable	Label	Value	N	%	<= 20
ANTIS	f8Gq12C1: ANT analysis inferoseptal	.	36	2.2	
		1	86	5.3	
		2	49	3.0	
		3	44	2.7	
		4	1328	82.6	
		5	56	3.5	
		6	9	0.6	*
ANTAS	f8Gq12C2: ANT analysis apical septum	.	36	2.2	
		1	125	7.8	
		2	73	4.5	
		3	60	3.7	
		4	1241	77.2	
		5	64	4.0	
		6	9	0.6	*
ANTAPX	f8Gq12C3: ANT analysis apex	.	36	2.2	
		1	252	15.7	
		2	90	5.6	
		3	67	4.2	
		4	1091	67.8	
		5	58	3.6	
		6	14	0.9	*
ANTAL	f8Gq12C4: ANT analysis anterolateral	.	36	2.2	
		1	76	4.7	
		2	34	2.1	
		3	44	2.7	
		4	1366	85.0	
		5	30	1.9	
		6	22	1.4	

(11FEB04--14:52)

T3B form8g

Variable	Label	Value	N	%	<= 20
ANTAB	f8Gq12C5: ANT analysis anterobasal	.	37	2.3	
		1	31	1.9	
		2	12	0.7	*
		3	23	1.4	
		4	1473	91.6	
		5	12	0.7	*
		6	20	1.2	*
ABLUNG	f8Gq13: Abnormal lung uptake	.	37	2.3	
		1	180	11.2	
		2	1391	86.5	
ABAMT	f8Gq13A: Lung uptake abnormality	.	1428	88.8	
		1	160	10.0	
		2	20	1.2	*
DILATE	f8Gq14: Transient LV dilatation	.	38	2.4	
		1	29	1.8	
		2	1541	95.8	
ANTISC	f8Gq15A: Reversible hypoperfusion visual	.	37	2.3	
		1	200	12.4	
		2	1371	85.3	
SEPISC	f8Gq15B: Reversible hypoperfusion visual	.	38	2.4	
		1	161	10.0	
		2	1409	87.6	
LATISC	f8Gq15C: Reversible hypoperfusion visual	.	38	2.4	
		1	162	10.1	
		2	1408	87.6	

(11FEB04--14:52)

T3B form8g

Variable	Label	Value	N	%	<= 20
IAISC	f8Gq15D: Reversible hypoperfusion visual	.	38	2.4	
		1	86	5.3	
		2	1484	92.3	
INFISC	f8Gq15E: Reversible hypoperfusion visual	.	38	2.4	
		1	239	14.9	
		2	1331	82.8	
APCISC	f8Gq15F: Reversible hypoperfusion visual	.	38	2.4	
		1	145	9.0	
		2	1425	88.6	
INTEGRAL	f8Gq20: Total defect integral	.	59	3.7	
		1	706	43.9	
		2	257	16.0	
		3	281	17.5	
		4	305	19.0	
REVERSAL	f8Gq21: Total percent reversibility	.	62	3.9	
		1	1124	69.9	
		2	196	12.2	
		3	226	14.1	
NOABNORM	f8Gq22A: No perfusion abnormality	.	44	2.7	
		1	628	39.1	
		2	936	58.2	
SCAR	f8Gq22B: Scar	.	46	2.9	
		1	611	38.0	
		2	951	59.1	

(11FEB04--14:52)

T3B form8g

Variable	Label	Value	N	%	<= 20
CLISCHEM	f8Gq22C: Reversible hypoperfusion	.	44	2.7	
		1	635	39.5	
		2	929	57.8	
LUISCHEM	f8Gq22D: Lung uptake with reversible hyp	.	44	2.7	
		1	114	7.1	
		2	1450	90.2	
CLDILATE	f8Gq22E: Transient LV dilatation	.	45	2.8	
		1	22	1.4	
		2	1541	95.8	
REVDIS	f8Gq22F: Reversible redistribution	.	90	5.6	
		1	167	10.4	
		2	1351	84.0	
ANTTERR	f8Gq22G1: Reversible hypoperfusion concl	.	88	5.5	
		1	190	11.8	
		2	1330	82.7	
SEPTERR	f8Gq22G2: Reversible hypoperfusion concl	.	88	5.5	
		1	176	10.9	
		2	1344	83.6	
LATTERR	f8Gq22G3: Reversible hypoperfusion concl	.	88	5.5	
		1	160	10.0	
		2	1360	84.6	
IAPTERR	f8Gq22G4: Reversible hypoperfusion concl	.	88	5.5	
		1	89	5.5	
		2	1431	89.0	

(11FEB04--14:52)

T3B form8g

Variable	Label	Value	N	%	<= 20
INFERR	f8Gq22G5: Reversible hypoperfusion concl	.	88	5.5	
		1	243	15.1	
		2	1277	79.4	
NCAPTERR	f8Gq22G6: Reversible hypoperfusion concl	.	88	5.5	
		1	105	6.5	
		2	1415	88.0	
HIGHRISK	f8Gq23: High risk patient	.	37	2.3	
		1	305	19.0	
		2	1266	78.7	
TWOERR	f8Gq23A1: Visual 2 or more reversible hy	.	1302	81.0	
		1	236	14.7	
		2	70	4.4	
LUANDIS	f8Gq23A2: Visual lung uptake & reversibl	.	1303	81.0	
		1	125	7.8	
		2	180	11.2	
HIGHWASH	f8Gq23A3: Quant lung washout > 42%	.	1305	81.2	
		1	29	1.8	
		2	274	17.0	
HIRATIO	f8Gq23A4: Quant lung//heart ratio > 0.5	.	1306	81.2	
		1	94	5.8	
		2	208	12.9	
DOUBLE	f8Gq23A5: Quant defect integral >=13 and	.	1305	81.2	
		1	57	3.5	
		2	246	15.3	

(11FEB04--14:52)

T3B form8g

Variable	Label	Value	N	%	<= 20
CLLVDIL	f8Gq23A3: Visual transient LV dilatation	.	1531	95.2	
		1	3	0.2	*
		2	74	4.6	
HIDILATE	f8Gq23A6: Dilatation index > 1.1	.	1499	93.2	
		1	1	0.1	*
		2	108	6.7	

T3B form8g

Variable	Label	N	Percentile	Value	n	<= 20
LAOUSRUA	f8Gq16A1A: LAO quant upper septum score	1553	5	0	1375	
			25	0	0	*
			50	0	0	*
			75	0	0	*
			95	3	117	
			100	13	61	
LAOUSRUB	f8Gq16A1B: LAO quant upper septum change	1547	5	-1	132	
			25	0	1372	
			50	0	0	*
			75	0	0	*
			95	0	0	*
			100	7	43	
LAOLSRUA	f8Gq16A2A: LAO quant lower septum score	1553	5	0	1266	
			25	0	0	*
			50	0	0	*
			75	0	0	*
			95	4	238	
			100	12	49	
LAOLSRUB	f8Gq16A2B: LAO quant lower septum change	1547	5	-2	94	
			25	0	1385	
			50	0	0	*
			75	0	0	*
			95	0	0	*
			100	4	68	

T3B form8g

Variable	Label	N	Percentile	Value	n	<= 20
LAOAPRUA	f8Gq16A3A: LAO quant apex score	1553	5	0	973	
			25	0	0	*
			50	0	0	*
			75	1	222	
			95	5	290	
			100	12	68	
LAOAPRUB	f8Gq16A3B: LAO quant apex change	1547	5	-2	176	
			25	-1	237	
			50	0	1027	
			75	0	0	*
			95	1	84	
			100	4	23	
LAOILRUA	f8Gq16A4A: LAO quant inferolateral score	1553	5	0	1074	
			25	0	0	*
			50	0	0	*
			75	1	178	
			95	5	248	
			100	13	53	
LAOILRUB	f8Gq16A4B: LAO quant inferolateral chang	1547	5	-2	94	
			25	0	1189	
			50	0	0	*
			75	0	0	*
			95	2	235	
			100	6	29	

T3B form8g

Variable	Label	N	Percentile	Value	n	<= 20
LAOPLRUA	f8Gq16A5A: LAO quant posterolateral scor	1553	5	0	1367	
			25	0	0	*
			50	0	0	*
			75	0	0	*
			95	2	132	
			100	11	54	
LAOPLRUB	f8Gq16A5B: LAO quant posterolateral chan	1547	5	-1	110	
			25	0	1346	
			50	0	0	*
			75	0	0	*
			95	1	64	
			100	4	27	
LATABRUA	f8Gq16B1A: LLAT quant anterobasal score	1547	5	0	1387	
			25	0	0	*
			50	0	0	*
			75	0	0	*
			95	1	96	
			100	10	64	
LATABRUB	f8Gq16B1B: LLAT quant anterobasal change	1540	5	-1	97	
			25	0	1372	
			50	0	0	*
			75	0	0	*
			95	0	0	*
			100	4	71	

T3B form8g

Variable	Label	N	Percentile	Value	n	<= 20
LATANRUA	f8Gq16B2A: LLAT quant anterior score	1547	5	0	1201	
			25	0	0	*
			50	0	0	*
			75	0	0	*
			95	4	289	
			100	11	57	
LATANRUB	f8Gq16B2B: LLAT quant anterior change	1540	5	-1	191	
			25	0	1187	
			50	0	0	*
			75	0	0	*
			95	1	110	
			100	7	52	
LATAPRUA	f8Gq16B3A: LLAT quant apex score	1547	5	0	1128	
			25	0	0	*
			50	0	0	*
			75	1	183	
			95	4	169	
			100	13	67	
LATAPRUB	f8Gq16B3B: LLAT quant apex change	1540	5	-1	241	
			25	0	1146	
			50	0	0	*
			75	0	0	*
			95	1	106	
			100	6	47	

T3B form8g

Variable	Label	N	Percentile	Value	n	<= 20
LATINRUA	f8Gq16B4A: LLAT quant inferior score	1547	5	0	1277	
			25	0	0	*
			50	0	0	*
			75	0	0	*
			95	3	214	
			100	9	56	
LATINRUB	f8Gq16B4B: LLAT quant inferior change	1540	5	-1	159	
			25	0	1287	
			50	0	0	*
			75	0	0	*
			95	1	69	
			100	4	25	
LATPBRUA	f8Gq16B5A: LLAT quant posterobasal score	1547	5	0	1364	
			25	0	0	*
			50	0	0	*
			75	0	0	*
			95	2	131	
			100	11	52	
LATPBRUB	f8Gq16B5B: LLAT quant posterobasal chang	1540	5	-1	86	
			25	0	1365	
			50	0	0	*
			75	0	0	*
			95	1	69	
			100	4	20	*

T3B form8g

Variable	Label	N	Percentile	Value	n	<= 20
ANTISRUA	f8Gq16C1A: ANT quant inferoseptal score	1552	5	0	1333	
			25	0	0	*
			50	0	0	*
			75	0	0	*
			95	2	161	
			100	7	58	
ANTISRUB	f8Gq16C1B: ANT quant inferoseptal change	1547	5	-1	129	
			25	0	1332	
			50	0	0	*
			75	0	0	*
			95	1	71	
			100	4	15	*
ANTASRUA	f8Gq16C2A: ANT quant apical septum score	1552	5	0	1104	
			25	0	0	*
			50	0	0	*
			75	1	189	
			95	4	198	
			100	10	61	
ANTASRUB	f8Gq16C2B: ANT quant apical septum chang	1547	5	-2	96	
			25	0	1336	
			50	0	0	*
			75	0	0	*
			95	1	95	
			100	4	20	*

T3B form8g

Variable	Label	N	Percentile	Value	n	<= 20
ANTAPRUA	f8Gq16C3A: ANT quant apex score	1552	5	0	1133	
			25	0	0	*
			50	0	0	*
			75	1	168	
			95	4	203	
			100	10	48	
ANTAPRUB	f8Gq16C3B: ANT quant apex change	1547	5	-2	86	
			25	0	1352	
			50	0	0	*
			75	0	0	*
			95	1	86	
			100	6	23	
ANTALRUA	f8Gq16C4A: ANT quant anterolateral score	1552	5	0	1375	
			25	0	0	*
			50	0	0	*
			75	0	0	*
			95	2	121	
			100	9	56	
ANTALRUB	f8Gq16C4B: ANT quant anterolateral chang	1547	5	-1	112	
			25	0	1359	
			50	0	0	*
			75	0	0	*
			95	0	0	*
			100	3	76	

T3B form8g

Variable	Label	N	Percentile	Value	n	<= 20
ANTABRUA	f8Gq16C5A: ANT quant anterobasal score	1552	5	0	1335	
			25	0	0	*
			50	0	0	*
			75	0	0	*
			95	2	157	
			100	9	60	
ANTABRUB	f8Gq16C5B: ANT quant anterobasal change	1548	5	-1	142	
			25	0	1329	
			50	0	0	*
			75	0	0	*
			95	0	0	*
			100	98	77	
EXDEFINT	f8Gq17A: Exercise defect integral	1552	5	0	439	
			25	0	0	*
			50	3	374	
			75	10	375	
			95	30	289	
			100	68	75	
CHDELIM	f8Gq17B: Change at delayed imaging	1546	5	-11	85	
			25	-3	346	
			50	0	676	
			75	1	159	
			95	4	207	
			100	20	73	

T3B form8g

Variable	Label	N	Percentile	Value	n	<= 20
RELCHANG	f8Gq17C: Relative change on delayed imag	1547	5	-99	159	
			25	-49	245	
			50	0	1118	
			75	0	0	*
			95	0	0	*
			100	99	25	
WASHOUT	f8Gq18: Lung washout	1548	5	0	145	
			25	14	243	
			50	23	415	
			75	30	404	
			95	40	269	
			100	96	72	
LHRATIO	f8Gq19: Lung/heart ratio	1551	5	0.26	89	
			25	0.34	355	
			50	0.4	398	
			75	0.46	324	
			95	0.58	310	
			100	0.79	75	
DILINDEX	f8Gq19: Dilatation index	390	5	0	283	
			25	0	0	*
			50	0	0	*
			75	0.92	11	*
			95	1.07	80	
			100	1.2	16	*

(11FEB04--14:52)

T3B form8g

Variable	Label	N	Mean	Std Dev	Minimum	Maximum
FM8GDAY	f8Gq2: Days to form	1607	18.4	25.3	1.0	378.0

(11FEB04--14:52)